Signaling pathway inhibitors, mirna, and nanocarrier-based pharmacotherapeutics for the treatment of lung cancer: a review

HIGHLIGHTS

  • who: Shadab Md and collaborators from the Department of, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia have published the research: Signaling Pathway Inhibitors, miRNA, and Nanocarrier-Based Pharmacotherapeutics for the Treatment of Lung Cancer: A Review, in the Journal: Pharmaceutics 2021, x of /2021/
  • what: The present review describes the mechanism and up-to-date possible therapeutic approaches for lung cancer treatment and emphasizes future prospects to bring these novel approaches from bench to bedside. A Phase II clinical trial was conducted to determine the efficacy of pazopanib among patients with NSCLC. Unfortunately . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?